Six Reasons Why Now Is A Good Time To Consider An ESOP
“…net employment at ESOPs climbed over 60% during 2001-2011 vs. no change elsewhere, concludes research by Alex Brill, CEO of consulting firm Matrix Global Advisors.”
New MGA Report on a Medicare Shared Savings Demonstration for Biosimilars
Matrix Global Advisors (MGA) today released a new report, “Shared Savings Demonstration for Biosimilars in Medicare: An Opportunity to Promote Biologic Drug Competition,” by MGA founder and CEO Alex Brill. The report identifies a unique opportunity in Medicare Part B to boost biosimilar utilization through the establishment of a shared savings demonstration model administered by the Centers for Medicare & Medicaid Services Innovation Center.
MGA’s Alex Brill on CNBC’s Squawk Box
“We want the program to work and I think that sadly what we’re seeing is that the program is working quite well. And I say sadly because we are seeing tens of millions of people process through that system and we’re going to continue to see that I think for the next few weeks as the backlogs in certain states get worked through…”
Small-Business Loan Fund May Run Dry Again. Is There Another Way?
“‘That could help accelerate the rebound if we can just kind of mothball the economy and then turn back on the same economy with the same manager-employee relationship,” said Alex Brill, a resident fellow at the right-leaning American Enterprise Institute.”
MGA’s Alex Brill Serves as a Panelist for “Biosimilars: Breaking Through the Barriers” Symposium
Alex Brill was one of the panelists discussing his “commitment to expand biosimilar use in the United States and how physicians and government officials are looking to help.
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
